NCT02691299View on ClinicalTrials.gov

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

527

Participants

Timeline

Start Date

December 9, 2015

Primary Completion Date

September 21, 2018

Study Completion Date

November 16, 2018

Conditions
NSCLC
Interventions
DRUG

Fruquintinib

Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off

DRUG

Placebo

Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off

Trial Locations (11)

100071

307 Hospital of PLA, Beijing

100142

Beijing Cancer Hospital, Beijing

101149

Beijing Chest Hospital, Beijing

130021

The First Hospital of Jilin University, Changchun

200000

The Cancer Hospital of Fudan University, Shanghai

200030

Shanghai Chest Hospital, Shanghai

226000

Nantong Tumor Hospital, Nantong

276001

Linyi Tumor Hospital, Linyi

310003

The First Affiliated Hosptial of College of Medicine, Zhejiang University, Hangzhou

510080

Guangdong General Hospital, Guangzhou

610041

West China Hospital, Chengdu

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT02691299 - A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter